Media

Centrient Pharmaceuticals* awarded second independent Minimized Risk of Antimicrobial Resistance (AMR) certification for Toansa, India Site

Strengthening Our Future in Delft: Pierre-Yves Dalla-Libera Appointed Site Director

Centrient Pharmaceuticals* publishes 2024 ESG Report, reaffirming commitment to sustainable and responsible manufacturing of medicines

Let’s Not Wait for the Next Crisis to Act on Medicine Supply Security

In today’s rapidly evolving landscape, Europe’s ability to manufacture foundational medicines is under growing pressure. In this blog, Centrient CEO Rex Clements explores why local antibiotic production is at risk — and what must be done to protect public health and ensure a resilient, sustainable supply. Read on to learn what’s at stake and how Centrient is stepping up.

Centrient Pharmaceuticals* (Centrient *) becomes member of the United Nations Global Compact (UNGC), strengthening commitment to ethical and sustainable business growth

Centrient Pharmaceuticals* supports European Critical Medicines Alliance recommendations in Strategic Report

Centrient Pharmaceuticals* opens Barcelona Innovation Laboratory to accelerate product and process development

Centrient’s SBTi-validated climate targets reinforce environmental commitment

Centrient ESG Report Confirms Continued Leadership in Sustainable Manufacturing of Medicines

Centrient Pharmaceuticals receives independent Minimized Risk of Antimicrobial Resistance (AMR) certification for Santa Perpetua, Spain Site